Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study

INTRODUCTION: Baricitinib, a JAK1/JAK2 inhibitor, is approved for treatment of moderate-to-severe rheumatoid arthritis (RA) in China. This single-arm, prospective, multi-center, post-marketing safety study (PMSS) evaluated the safety and effectiveness of baricitinib in Chinese patients. METHODS: Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chan-yuan, Wang, Qian, Shi, Jian, Zhang, Xiu-ying, Du, Rong, Gu, Jie-ruo, Liu, Qi-huan, Yu, Jiao, Xu, Jia-wei, Zhang, Yan-jie, Zhu, Hao, Li, Meng-tao, Zeng, Xiao-feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654295/
https://www.ncbi.nlm.nih.gov/pubmed/37768505
http://dx.doi.org/10.1007/s40744-023-00596-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654295/
https://www.ncbi.nlm.nih.gov/pubmed/37768505
http://dx.doi.org/10.1007/s40744-023-00596-4

Ejemplares similares